Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

Viking Therapeutics

Obesity Weekly News

Obesity Video Recap—November 25, 2025

This biweekly obesity video recap covers late-stage obesity trial readouts,…

Obesity Weekly News

Obesity Today—November 25, 2025

This week’s obesity update brings you the latest clinical advancements,…

Obesity Weekly News

Obesity Video Recap—November 11, 2025

This biweekly obesity video recap reviews major moves shaping the obesity and…

Obesity Weekly News

Obesity Weekly News - July 1st 2025

Fractyl’s Gene Therapy Breakthrough, Verdiva’s Oral GLP-1 Pipeline, Viking’s…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Respiratory Video Recap—November 28, 2025
Vaccines Video Recap—November 28, 2025
Public Health Today—28 November, 2025

Tags

AIRSUPRA Annamycin ATyr Pharma AVT03 bimagrumab cabozantinib CAP-002 Cedars-Sinai CHD China in-licensing chlamydia Cortical Labs CL1 Cytisinicline DHEA-S ELI-002 Eli Lilly TuneLab European Society of Cardiology exclusivity FDA CRL GIPR HDP-101 hearth health IBTROZI Icotrokinra IgG4-RD insulin icodec KOSELUGO Lumefantrine Mandos Health MAVENCLAD mitazalimab NHG nicotinamide nmCRPC OX40 Prefusion F Preterm birth quetiapine XR Rgenta Therapeutics Roche Carmot CT-388 Solid Biosciences Strive Health Syndax Valoctocogene Roxaparvovec vimseltinib

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Respiratory Video Recap—November 28, 2025
Vaccines Video Recap—November 28, 2025
Public Health Today—28 November, 2025

TAGS

AIRSUPRA Annamycin ATyr Pharma AVT03 bimagrumab cabozantinib CAP-002 Cedars-Sinai CHD China in-licensing chlamydia Cortical Labs CL1 Cytisinicline DHEA-S ELI-002 Eli Lilly TuneLab European Society of Cardiology exclusivity FDA CRL GIPR HDP-101 hearth health IBTROZI Icotrokinra IgG4-RD insulin icodec KOSELUGO Lumefantrine Mandos Health MAVENCLAD mitazalimab NHG nicotinamide nmCRPC OX40 Prefusion F Preterm birth quetiapine XR Rgenta Therapeutics Roche Carmot CT-388 Solid Biosciences Strive Health Syndax Valoctocogene Roxaparvovec vimseltinib

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy